ZVRA

Zevra

--(--)

Market Open: --

--(--)

Post-Market: --

Signals Analysis

Buy signal 3

Sell signal 2

stock price surged significantly

consensus rating "Strong Buy"

MACD Golden Cross

EPS Below Expectations

Revenue Below Expectations

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

Prev.Close

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

Low

52 Week High

52 Week Low

About ZVRA

Zevra Therapeutics, Inc.

A specialty pharmaceutical company focused on treatments for rare central nervous system, neurodegenerative and lysosomal storage diseases

Industry

Pharmaceutical

Established Date

Invalid Date

Listing Date

01/08/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.zevra.com

Security Type

Common stock

Office address

1180 Celebration Boulevard, Suite 103, Celebration, FL 34747

Business

Introduction

Zevra Therapeutics, Inc., was incorporated in Iowa in October 2006 and reorganized in Delaware in May 2014. The company is a rare disease company that combines science, data and patient needs to create translational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapies to people with rare diseases. With a unique, data-driven development and commercialization strategy, the company is overcoming complex drug development challenges to deliver new therapies to the rare disease community. The company has a diverse product portfolio and product candidates that include preclinical development programs, clinical-stage pipelines and commercial-stage assets. The company's team has expertise and a successful track record of advancing promising therapies that face complex clinical and regulatory challenges by balancing science and data with patient needs.

Company Financials

EPS

ZVRA has released its 2024 Q4 earnings. EPS was reported at -0.67, versus the expected -0.40, missing expectations. The chart below visualizes how ZVRA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ZVRA has released its 2024 Q4 earnings report, with revenue of 12.04M, reflecting a YoY change of -6.79%, and net profit of -35.74M, showing a YoY change of -79.67%. The Sankey diagram below clearly presents ZVRA’s revenue sources and cost distribution.